Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:12 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1945–1968 of 7,258 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: High-Risk Clear all

Conditions: Anxiety, Carpal Tunnel Syndrome, Trigger Finger, Engagement, Patient, Pain
Interventions: High-quality, physician created video, Standard of care; Other
Lead sponsor: Northwell Health; Other
Eligibility: 18 Years and older
Enrollment: 167 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 1
States / cities: Manhasset, New York

Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
Interventions: High Dose Methylprednisolone (HDMP), Ofatumumab, Lenalidomide; Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 29 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2020
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Violence
Interventions: Miles de Manos (Thousands of Hands); Behavioral
Lead sponsor: University of Texas at Austin; Other
Eligibility: 7 Years to 99 Years
Enrollment: 3,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Breast Cancer
Interventions: Cholecalciferol; Drug
Lead sponsor: Katherine D. Crew; Other
Eligibility: 21 Years and older · Female only
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: Prostate Cancer
Interventions: bevacizumab, bicalutamide and goserelin, intensity modulated radiation therapy (IMRT); Drug · Procedure
Lead sponsor: Benaroya Research Institute; Other
Eligibility: 18 Years and older · Male only
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2006
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity
Interventions: Placebo, MUFA, PUFA, SFA; Dietary Supplement
Lead sponsor: Vanderbilt University; Other
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Breast Cancer
Interventions: Ribociclib, Postoperative Radiation Therapy; Drug · Radiation
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2030
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Wyoming, Michigan • Cleveland, Ohio

Conditions: High-need, High-complexity
Interventions: Primary Hospital Provider Team; Other
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years and older
Enrollment: 1,200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Gastro-enteropancreatic Neuroendocrine Tumor, Pancreatic Cancer, Neuroendocrine Carcinomas of Pancreas, Islet Cell Carcinoma
Interventions: FOLFIRINOX, Granulocyte colony-stimulating factor (G-CSF); Drug
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2018
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Diffuse Midline Glioma or Diffuse Intrinsic Pontine Glioma, High Grade Gliomas, Medulloblastoma Recurrent, Ependymoma Recurrent, Atypical Teratoid/Rhabdoid Tumor (ATRT) of the CNS, Brain Tumor Recurrent
Interventions: NeuroNavigation-Guided Focused Ultrasound (NgFUS), Lumason, Nivolumab; Device · Drug
Lead sponsor: Children's National Research Institute; Other
Eligibility: 3 Years to 25 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Washington D.C., District of Columbia

Conditions: Esophageal Stenosis
Interventions: prednisone, placebo; Drug
Lead sponsor: AdventHealth; Other
Eligibility: 18 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Orlando, Florida

Conditions: Non-melanoma Skin Cancer
Interventions: UAB30, Placebo; Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Opioid-use Disorder, Neonatal Abstinence Syndrome, Pregnancy, High Risk, Alcohol Use Disorder
Interventions: Pharmacokinetic analysis, Safety and Efficacy, Genetic and epigenetic analysis, Breast milk analysis; Other · Genetic
Lead sponsor: Boston Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2024
U.S. locations: 2
States / cities: Boston, Massachusetts • Carrboro, North Carolina

Conditions: High Risk Pregnancy, Cesarean Wound Disruption With Postnatal Complication
Interventions: PICO Single Use Negative Pressure Wound Therapy; Device
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older · Female only
Enrollment: 154 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Surgical Site Infection
Interventions: high-fiber, fermented; Behavioral
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Stanford, California

Conditions: Fatty Liver
Interventions: Not listed
Lead sponsor: Methodist Health System; Other
Eligibility: 18 Years and older
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Dallas, Texas

Conditions: Malignant Melanoma
Interventions: GM-CSF; Drug
Lead sponsor: Mt. Sinai Medical Center, Miami; Other
Eligibility: 16 Years to 90 Years
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 2
States / cities: Miami Beach, Florida • Atlanta, Georgia

Conditions: Brain and Central Nervous System Tumors, Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: irinotecan hydrochloride, temozolomide, vincristine sulfate; Drug
Lead sponsor: Children's Oncology Group; Network
Eligibility: 1 Year to 21 Years
Enrollment: 42 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2011
U.S. locations: 16
States / cities: Birmingham, Alabama • Orange, California • Stanford, California + 13 more

Conditions: Pelvic Floor Disorders, Pelvic Pain
Interventions: Diazepam, Placebo; Drug
Lead sponsor: Raymond Foster; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Gonorrhoea
Interventions: Cefixime; Drug
Lead sponsor: National Institute of Allergy and Infectious Diseases (NIAID); NIH
Eligibility: 18 Years to 45 Years
Enrollment: 25 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Lymphoma
Interventions: rituximab, Cyclophosphamide, doxorubicin hydrochloride, prednisone, vincristine sulfate, radiation therapy, Yttrium-90 ibritumomab tiuxetan, Indium-111 ibritumomab tiuxetan; Biological · Drug · Radiation
Lead sponsor: SWOG Cancer Research Network; Network
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2015
U.S. locations: 48
States / cities: Anchorage, Alaska • Burbank, California • Boise, Idaho + 33 more

Conditions: Anaplastic Oligodendroglioma, Oligoastrocytoma, Oligodendroglioma
Interventions: Wear novoTTF-200A, Quality-of-Life Assessment; Device · Procedure
Lead sponsor: University of Southern California; Other
Eligibility: 19 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Infertility, Breast Cancer
Interventions: RPFNA; Procedure
Lead sponsor: University of Kansas; Other
Eligibility: 21 Years to 45 Years · Female only
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Oral Leukoplakia
Interventions: pioglitazone-metformin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years and older
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: Minneapolis, Minnesota • Saint Paul, Minnesota

Search by objective public record fields.

Effect of High-quality Pre-operative Videos on Patient Anxiety Levels Prior to Ambulatory Hand Surgery

Ofatumumab/Methylprednisolone and Ofatumumab/Lenalidomide for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

A Randomized Controlled Trial of Miles de Manos (Thousands of Hands)

Study of Vitamin D for Premenopausal Women at High Risk for Breast Cancer

Bevacizumab With Hormonal and Radiotherapy for High-Risk Prostate Cancer

High Fat Diet: Oxidative and Cardiovascular Effects

Study of Ribociclib Administered Concurrently With Postoperative Radiation Therapy in Patients With High-Risk, HR+/HER2- Breast Cancer

Implementation of a Primary Hospital Provider (PHP) Team

FOLFIRINOX in Metastatic High Grade Gastroenteropancreatic Neuroendocrine Carcinomas

NgFUS NIVO: NeuroNavigation-Guided Focused Ultrasound With Nivolumab in Relapsed and Progressive DMG and Other High Grade Brain Tumors

Reduction in Symptomatic Esophageal Stricture Formation

A Biomarker Evaluation Trial of UAB30 in Renal Transplant Recipients at High Risk for Non-melanoma Skin Cancer

MOM NEST Study: Maternal Opioid Medication: Naltrexone Efficacy Study

Negative Pressure Wound Therapy to Prevent Wound Complications Following Cesarean Section in High Risk Patients

Effect of Preoperative Diet on Perioperative Gut Microbiome

Exploratory Analysis of Enhanced Liver Function (ELF) Test to Detect Early Fatty Liver in High Risk Population

Phase II Trial of (IL-2) With Priming and (GM-CSF) in Patients With Advanced Melanoma

Temozolomide, Vincristine, and Irinotecan in Treating Young Patients With Refractory Solid Tumors

Vaginal Diazepam for the Treatment of Female Pelvic Pain

The Pharmacokinetics of Extended Duration High-dose Cefixime for the Decreased Susceptibility of Neisseria Gonorrhoeae: A Phase I Pilot Study

S0313 Cyclophosphamide, Doxorubicin, Vincristine, Prednisone, and Radiation Therapy Followed By Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Stage I or Stage II Non-Hodgkin's Lymphoma

NovoTTF-200A Device in Treating Patients With Newly Diagnosed High Risk Oligodendroglioma

Effects of Controlled Ovarian Hyperstimulation (COH) With Letrozole and Gonadotropin

Pioglitazone-Metformin Combination Treatment for High Risk Oral Preneoplasia